ALT
HEALTHCAREAltimmune Inc
AI Insight
What's Moving ALT Today?
No stock-specific AI insight has been generated for ALT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.56$6.44
$2.97
Fundamentals
Market Cap$577M
P/E Ratio—
EPS$-0.92
Dividend Yield—
Dividend / Share—
ROE-42.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding194.5M
ALT News
23 articles- Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?Yahoo Finance·Jun 24, 2026
- Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic DataYahoo Finance·Jun 17, 2026
- Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?Yahoo Finance·Jun 12, 2026
- Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data NearMarketbeat·Jun 10, 2026
- Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightYahoo Finance·Jun 8, 2026
- ALT and the Rise of Dual Agonists Targeting Liver DiseaseYahoo Finance·Jun 8, 2026
- ALT Stock Guide to Pemvidutide's MASH, AUD and ALD SetupYahoo Finance·Jun 8, 2026
- Is Altimmune Worth Buying Ahead of 2026 Catalysts?Yahoo Finance·Jun 8, 2026
- Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH TrialMarketbeat·Jun 5, 2026
- Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026Yahoo Finance·May 28, 2026
- Altimmune to Participate in Upcoming Investor ConferencesYahoo Finance·May 27, 2026
- New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026Yahoo Finance·May 27, 2026
- Here's Why You Should Add Altimmune Stock to Your Portfolio NowYahoo Finance·May 22, 2026
- Altimmune's Q1 Loss Narrower Than Expected, Revenues NilYahoo Finance·May 14, 2026
- Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ...Yahoo Finance·May 13, 2026
- Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong CasGuruFocus·May 13, 2026
- Altimmune (ALT) Q1 2026 Earnings TranscriptMotley Fool·May 13, 2026
- Altimmune, Inc. Q1 2026 Earnings Call SummaryMoby·May 13, 2026
- Altimmune Q1 Earnings Call HighlightsMarketbeat·May 13, 2026
- Altimmune Q1 2026 Earnings Call: Complete TranscriptYahoo Finance·May 13, 2026
- Altimmune shares climb after first-quarter loss beats expectations (ALT)Advfn·May 13, 2026
- Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswire Inc.·Apr 23, 2026
- Anti-Aging Protein Research Takes a Step Forward with Cell CloningBenzinga·Mar 24, 2026
All 23 articles loaded
Price Data
Open$2.92
Previous Close$2.91
Day High$3.04
Day Low$2.92
52 Week High$6.44
52 Week Low$2.56
52-Week Range
$2.56$6.44
$2.97
Fundamentals
Market Cap$577M
P/E Ratio—
EPS$-0.92
Dividend Yield—
Dividend / Share—
ROE-42.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding194.5M
About Altimmune Inc
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—